Tonix Pharmaceuticals Holding Corp
NASDAQ:TNXP
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Tonix Pharmaceuticals Holding Corp
NASDAQ:TNXP
|
US |
|
Online Vacation Center Holdings Corp
OTC:ONVC
|
US |
|
S
|
Seowon Co Ltd
KRX:021050
|
KR |
|
Kloeckner & Co SE
OTC:KLKNF
|
DE |
|
E
|
Engcon AB
F:917
|
SE |
|
N
|
NextSource Materials Inc
OTC:NSRCF
|
CA |
|
Uber Technologies Inc
NYSE:UBER
|
US |
|
NU Skin Enterprises Inc
NYSE:NUS
|
US |
|
S
|
Shandong Dongyue Organosilicon Materials Co Ltd
SZSE:300821
|
CN |
|
Indah Kiat Pulp & Paper Tbk PT
IDX:INKP
|
ID |
|
D
|
Daewon Cable Co Ltd
KRX:006340
|
KR |
|
I
|
IBKimyoung Co Ltd
KOSDAQ:339950
|
KR |
Tonix Pharmaceuticals Holding Corp
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. The company is headquartered in Chatham, New Jersey and currently employs 73 full-time employees. The company went IPO on 2010-03-29. The company is focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonixs portfolio is primarily composed of immunology and central nervous system (CNS) and infectious disease product candidates. Its immunology portfolio includes biologics to address organ transplant rejection, autoimmune diseases, and cancer. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Its infectious disease portfolio of product candidates includes vaccines to prevent COVID-19, an antiviral to treat COVID-19, and treatment for long COVID. The infectious disease portfolio also includes a vaccine in development to prevent smallpox and monkeypox. Its product candidates include TNX-1500, TNX-1300, TNX-102 SL, TNX-102 SL, TNX-102 SL,TNX-1900,TNX-601 CR, and TNX-1900.
Tonix Pharmaceuticals Holding Corp. is a clinical-stage biopharmaceutical company, which focuses on the discovery, acquisition, and development of small molecules and biologics to treat and prevent human disease and alleviate suffering. The company is headquartered in Chatham, New Jersey and currently employs 73 full-time employees. The company went IPO on 2010-03-29. The company is focused on discovering, licensing, acquiring and developing small molecules and biologics to treat and prevent human disease and alleviate suffering. Tonixs portfolio is primarily composed of immunology and central nervous system (CNS) and infectious disease product candidates. Its immunology portfolio includes biologics to address organ transplant rejection, autoimmune diseases, and cancer. The CNS portfolio includes small molecules and biologics to treat pain, neurologic, psychiatric and addiction conditions. Its infectious disease portfolio of product candidates includes vaccines to prevent COVID-19, an antiviral to treat COVID-19, and treatment for long COVID. The infectious disease portfolio also includes a vaccine in development to prevent smallpox and monkeypox. Its product candidates include TNX-1500, TNX-1300, TNX-102 SL, TNX-102 SL, TNX-102 SL,TNX-1900,TNX-601 CR, and TNX-1900.
